Previous 10 | Next 10 |
2024-06-24 09:21:19 ET More on Altimmune Altimmune: Going All-In On Pemvidutide Altimmune: A Potential Minor Player In The Massive GLP-1 Space Altimmune's Pemvidutide Is Not To Be Dismissed Altimmune Q1 2024 Earnings Preview Altimmune falls after Q4 r...
2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...
2024-06-22 11:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly And Alzheimer's Disease: The Paucity Of Progress ResMed, Philips under pressur...
2024-06-21 10:03:58 ET More on Catalent Catalent shareholders approve acquisition by Novo Holdings Catalent, Novo Nordisk receive FTC request for more information Seeking Alpha’s Quant Rating on Catalent Historical earnings data for Catalent Fi...
2024-06-21 09:44:16 ET More on Hims & Hers Health Hims & Hers: The Undervalued Gem Poised For Growth Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead Hims & Hers: Ready For Takeoff Hims & Hers cut to Neutra...
2024-06-21 08:30:00 ET Ozempic has become the big name associated with weight loss. Although there are other competing drugs which could take market share from it in the future, the diabetes treatment has become well known on social media for its ability to help people lose weight. And th...
2024-06-21 08:20:43 ET More on Zealand Pharma Zealand Pharma A/S (ZLDPF) Q1 2024 Earnings Call Transcript Zealand, Boehringer liver disease drug survodutide shows fibrosis improvement Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide ...
2024-06-21 06:56:18 ET Summary Qualcomm stock dips after reports of compatibility issues with Samsung's new laptop. Canada planning tariffs on Chinese EV imports, following U.S. and EU actions. WHO warns of fake versions of Novo Nordisk's diabetes medication, Ozempic. ...
2024-06-20 15:09:50 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo reports new fire at...
2024-06-20 09:02:55 ET More on Eli Lilly Eli Lilly: The Party Is Probably Nearing The End Eli Lilly And Alzheimer's Disease: The Paucity Of Progress Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly oral weight-loss candidate orforglipron is pote...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...
2024-07-13 17:52:00 ET Novo Nordisk (NYSE: NVO) is already a stock that's easy to justify buying. Between the incredible success of Ozempic, tons of demand for its weight loss medicine, and big investments in manufacturing as well as its pipeline, optimism about its future is practi...